Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11578825 | 0.85 | HCAR2 (0.62) | HCAR2 | |
| SCHEMBL1867121 | 0.83 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL1870049 | 0.82 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL1868458 | 0.82 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL1876556 | 0.80 | HCAR2 (0.79) | HCAR2 | |
| SCHEMBL1870059 | 0.80 | HCAR2 (0.79) | HCAR2 | |
| SCHEMBL1871754 | 0.80 | HCAR2 (0.85) | HCAR2 | |
| SCHEMBL1872828 | 0.80 | HCAR2 (0.74) | HCAR2 | |
| SCHEMBL1871441 | 0.80 | HCAR2 (0.67) | HCAR2PARP1 | |
| SCHEMBL1870370 | 0.79 | HCAR2 (0.80) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479830-B2 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2025-11-25 | — | — | US | disclosed |
| US-20220380345-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-12-01 | — | — | US | disclosed |
| EP-0407342-A2 | Pyrimidine derivatives | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479830-B2 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | HCAR2 247/4885PARP1 1936/4885 |
| US-20220380345-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | HCAR2 247/4885PARP1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.